Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Immuno-Oncology 2.0 Roundtable: Scientific And Pricing Challenges Can't Slow New Therapies

Mar 07 2017

• By Mandy Jackson

Cancer-cells-pink-color_1200x675

Related Content

Startups Stand Out As 13 Biotechs Raise More Than $409m

Dec 18 2015

Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition

Oct 11 2016

Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline

Dec 02 2016

Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Jun 28 2016

Is the Biotech IPO Window Closing?

Oct 22 2015

Tocagen Aims Double Barrels At Glioma

Feb 01 2017

Pipeline Watch: Evolocumab, Roxadustat And SB-204, Top-line Results

Feb 06 2017

Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field

Mar 03 2017

Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan

Jan 12 2017

Related Companies

Tocagen, Inc.

CytomX Therapeutics, Inc.

Trillium Therapeutics Inc.

Xencor, Inc.

Poseida Therapeutics, Inc.

Tocagen, Inc.

CytomX Therapeutics, Inc.

Bristol Myers Squibb Company

Roche Holding AG

Trillium Therapeutics Inc.

Xencor, Inc.

Novartis AG

Johnson & Johnson

MorphoSys AG

Boehringer Ingelheim GmbH

Poseida Therapeutics, Inc.

Bristol Myers Squibb Company

AstraZeneca PLC

Additional Topics

Clinical Trials ImmunoOncology Pricing Strategies Reimbursement Commercial BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window